Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
30 July 2015Website:
http://www.vtvtherapeutics.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 28 Jun 2024 20:00:01 GMTDividend
Analysts recommendations
Institutional Ownership
VTVT Latest News
Cadisegliatin is a potential first-in-class oral liver selective glucokinase activator for T1D, which has been granted Breakthrough Therapy designation by the FDA for T1D
WESTON, Fla. , May 28, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that Cantex's azeliragon, a well-tolerated once-a-day pill that inhibits "RAGE" (the receptor for advanced glycation end products), will be featured in four abstracts at this year's 2024 ASCO Annual Meeting to be held in Chicago.
WESTON, Fla. , June 15, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, today announced that it will present at the MedInvest Oncology Investor Conference being held June 21-22, 2023, in Boston, MA.
What type of business is vTv Therapeutics?
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
What sector is vTv Therapeutics in?
vTv Therapeutics is in the Healthcare sector
What industry is vTv Therapeutics in?
vTv Therapeutics is in the Biotechnology industry
What country is vTv Therapeutics from?
vTv Therapeutics is headquartered in United States
When did vTv Therapeutics go public?
vTv Therapeutics initial public offering (IPO) was on 30 July 2015
What is vTv Therapeutics website?
https://www.vtvtherapeutics.com
Is vTv Therapeutics in the S&P 500?
No, vTv Therapeutics is not included in the S&P 500 index
Is vTv Therapeutics in the NASDAQ 100?
No, vTv Therapeutics is not included in the NASDAQ 100 index
Is vTv Therapeutics in the Dow Jones?
No, vTv Therapeutics is not included in the Dow Jones index
When does vTv Therapeutics report earnings?
The next expected earnings date for vTv Therapeutics is 09 August 2024